{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-lazcluze-lazertinib-with-prophylactic-strategies-shows-low-rates-of-treatment-related-events-at-wclc-2026-302878165.html", "message": "News view counter 933345 successfully enlarged"}